Sofinnova Partners has closed its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million), exceeding its initial target. The fund will invest in early-stage biopharmaceutical and medical technology companies across Europe and North America.
The fund attracted support from institutional investors including sovereign wealth funds, pharmaceutical companies, corporates, insurance companies, foundations, and family offices. Commitments came from Europe, North America, Asia, and the Middle East, with a majority of returning limited partners and new investors.
“This fundraising marks a pivotal moment for Sofinnova,” said Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners. “It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach.”
Sofinnova Capital XI is actively deploying capital and has made investments in portfolio companies. The fund will support early-stage biotech and medtech ventures in both initial and follow-on rounds.
The fund’s team includes Partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.
Total capital raised across Sofinnova’s platform reached €1.5 billion over the past year.
Sofinnova Partners is a European venture capital firm based in Paris, London, and Milan specializing in life sciences, healthcare, and sustainability. Founded in 1972, the firm has backed over 500 companies and manages over €4 billion in assets.
